Trial Profile
A Proof-of-concept Study to Assess the Effect of Recombinant Human Growth Hormone on the Size of the Replication-competent Viral Reservoir in HIV-infected Individuals on Suppressive Antiretroviral Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Somatropin (Primary)
- Indications HIV-1 infections
- Focus Proof of concept; Therapeutic Use
- 11 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 13 Mar 2023 Planned End Date changed from 1 Dec 2020 to 1 Dec 2023.
- 13 Mar 2023 Status changed from recruiting to active, no longer recruiting.